TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.
CHICAGO--(BUSINESS WIRE)-- Northwestern Medicine and Tempus AI, Inc. (TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide ...
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
Tempus AI TEM sits at the intersection of diagnostics, data and artificial intelligence. The company is building a precision medicine platform designed to help physicians, researchers and drug ...
Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient ...
CHICAGO - Northwestern Medicine and Tempus AI, Inc. (NASDAQ:TEM) announced a collaboration to broaden access to genomic testing for cancer patients across Northwestern Medicine’s network, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results